← Leaderboards
Saul R Tzipori
Tufts University Boston
$24,857,188
Attributed
$28,247,634
Total exposure
24
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,247,634 · 24
By mechanism
R01$13,740,054 · 8
U19$5,437,866 · 1
N01$3,536,182 · 1
R21$2,306,062 · 5
U01$1,345,823 · 1
R56$897,906 · 1
Top collaborators
- Hanping Feng6 shared
- Charles Bix Shoemaker3 shared
- Amanda Martinot2 shared
- Rebecca Sandlin2 shared
- Terry L Bowlin1 shared
- Rosangela Mezghanni1 shared
Most similar at Tufts University Boston
Same institution · by research overlap
- Charles Bix Shoemaker$9,649,281
- Joan C. Mecsas$15,947,302
- Donna E Akiyoshi$1,949,457
- Saul W Tzipori$1,424,114
- Giovanni Widmer$5,928,799
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionDiarrheaCryptosporidiosisLaboratoriesMorbidity - Disease RateCryptosporidiumPathogenEnteralGnotobioticAcuteBaseOralChildParasitesVaccinesProteinsLifePreventionMediatingResponseSwineAnimalsMortality Vital StatisticsCryptosporidium Parvum
Grant awards (64)
In vitro cultivation and genome sequencing/annotation of Enterocytozoon bieneusi$412,377
R61 · FY2025 · AI · contact PI
Immune-based therapy against STEC intoxication and HUS$466,864
R01 · FY2023 · AI · contact PI
Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters$206,250
R21 · FY2023 · AI
Immune-based therapy against STEC intoxication and HUS$463,531
R01 · FY2022 · AI · contact PI
Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters$247,500
R21 · FY2022 · AI
Immune-based therapy against STEC intoxication and HUS$472,682
R01 · FY2021 · AI · contact PI
Optimizing and expanding cryopreservation of Cryptosporidium oocysts$208,050
R21 · FY2021 · AI
Identifying target antigens for Cryptosporidium vaccine$206,250
R21 · FY2021 · AI · contact PI
Optimizing and expanding cryopreservation of Cryptosporidium oocysts$266,600
R21 · FY2020 · AI
Identifying target antigens for Cryptosporidium vaccine$247,500
R21 · FY2020 · AI · contact PI
Development of strategies to achieve immunoprotection against Cryptosporidiosis$893,439
U19 · FY2018 · AI · contact PI
Development of strategies to achieve immunoprotection against Cryptosporidiosis$1,020,665
U19 · FY2017 · AI · contact PI
Development of strategies to achieve immunoprotection against Cryptosporidiosis$1,012,009
U19 · FY2016 · AI · contact PI
Development of strategies to achieve immunoprotection against Cryptosporidiosis$1,219,632
U19 · FY2015 · AI · contact PI
Development of strategies to achieve immunoprotection against Cryptosporidiosis$1,292,121
U19 · FY2014 · AI · contact PI
Development of Vaccines against Clostridium difficile Infection$631,430
R01 · FY2014 · AI
Development of Vaccines against Clostridium difficile Infection$594,490
R01 · FY2013 · AI
Development of Vaccines against Clostridium difficile Infection$639,528
R01 · FY2012 · AI
Evaluation of a new class of antimicrobial agents against Clostridium difficile$897,906
R56 · FY2011 · AI · contact PI
Development of Vaccines against Clostridium difficile Infection$309,454
R01 · FY2011 · AI
Development of Vaccines against Clostridium difficile Infection$300,283
R01 · FY2011 · AI
Development of Aptamer-Based Therapy Against HUS$664,732
U01 · FY2010 · AI · contact PI
Development of Vaccines against Clostridium difficile Infection$663,948
R01 · FY2010 · AI
Innate immunity and dendritic cells in cryptosporidiosis$307,653
R01 · FY2010 · AI · contact PI
Food & Waterborne Diseases Integrated Research Network$3,157,811
N01 · FY2009 · AI · contact PI
Development of Aptamer-Based Therapy Against HUS$681,091
U01 · FY2009 · AI · contact PI
Innate immunity and dendritic cells in cryptosporidiosis$389,823
R01 · FY2009 · AI · contact PI
Food & Waterborne Diseases Integrated Research Network$201,562
N01 · FY2009 · AI · contact PI
Food & Waterborne Diseases Integrated Research Network$176,809
N01 · FY2009 · AI · contact PI
REGULATION OF INNATE IMMUNITY TO ENTEROCYTOZOON BIENEUSI INFECTION$111,945
P51 · FY2009 · RR · contact PI
Innate immunity and dendritic cells in cryptosporidiosis$389,823
R01 · FY2008 · AI · contact PI
INNATE IMMUNITY OF ENTEROCYTOZOON BIENEUSI (EB) IN VIVO$55,151
P51 · FY2008 · RR · contact PI
Innate immunity and dendritic cells in cryptosporidiosis$412,787
R01 · FY2007 · AI · contact PI
Specific Human Monoclonal Antibodies for HUS Prophylaxis$338,145
R01 · FY2007 · AI · contact PI
Regulation of Innate Immunity to Enterocytozoon bieneusi Infection$238,987
R21 · FY2007 · AI · contact PI
CONTRIBUTION OF OIS TO INTESTINAL DYSFUNCTION AND WASTING$103,634
P51 · FY2007 · RR · contact PI
Studies on Cryptosporidium parvum Type 1$386,938
R01 · FY2006 · AI · contact PI
Specific Human Monoclonal Antibodies for HUS Prophylaxis$348,245
R01 · FY2006 · AI · contact PI
Innate immunity and dendritic cells in cryptosporidiosis$342,115
R01 · FY2006 · AI · contact PI
Regulation of Innate Immunity to Enterocytozoon bieneusi Infection$221,125
R21 · FY2006 · AI · contact PI
CONTRIBUTION OF OIS TO INTESTINAL DYSFUNCTION AND WASTING$134,807
P51 · FY2006 · RR · contact PI
Studies on Cryptosporidium parvum Type 1$396,250
R01 · FY2005 · AI
Specific Human Monoclonal Antibodies for HUS Prophylaxis$356,625
R01 · FY2005 · AI
Studies on Cryptosporidium parvum Type 1$396,250
R01 · FY2004 · AI
Specific Human Monoclonal Antibodies for HUS Prophylaxis$356,625
R01 · FY2004 · AI
RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES$334,000
R01 · FY2004 · DK
CONTRIBUTION OF OIS TO INTESTINAL DYSFUNCTION &WASTING$64,424
P51 · FY2004 · RR
Studies on Cryptosporidium parvum Type 1$396,250
R01 · FY2003 · AI
RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES$334,000
R01 · FY2003 · DK
Generation of Reagents for E. bieneusi Genome Sequencing$231,900
R21 · FY2003 · AI
Specific Human Monoclonal Antibodies for HUS Prophylaxis$178,313
R01 · FY2003 · AI
CONTRIBUTION OF OIS TO INTESTINAL DYSFUNCTION AND WASTING$101,403
P51 · FY2003 · RR
Studies on Cryptosporidium parvum Type 1$396,250
R01 · FY2002 · AI
RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES$334,000
R01 · FY2002 · DK
PIG MODEL FOR E BIENEUSI$333,199
R01 · FY2002 · AI
IMMUNITY TO CRYPTOSPORIDIOSIS IN SIV INFECTED MACAQUES$298,005
R01 · FY2002 · RR
Generation of Reagents for E. bieneusi Genome Sequencing$231,900
R21 · FY2002 · AI
RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES$334,000
R01 · FY2001 · DK
PIG MODEL FOR E BIENEUSI$323,493
R01 · FY2001 · AI
IMMUNITY TO CRYPTOSPORIDIOSIS IN SIV INFECTED MACAQUES$289,331
R01 · FY2001 · RR
RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES$334,000
R01 · FY2000 · DK
PIG MODEL FOR E BIENEUSI$314,071
R01 · FY2000 · AI
SITE SPECIFIC HU MONOCLONAL ANTIBODIES--HUS PROPHYLAXIS$306,969
R01 · FY2000 · AI
IMMUNITY TO CRYPTOSPORIDIOSIS IN SIV INFECTED MACAQUES$270,684
R01 · FY2000 · RR